Confirmed objective response rate (ORR) with ENHERTU plus pertuzumab was ... the DESTINY-Breast09 results show trastuzumab deruxtecan combined with pertuzumab has the potential to become a new ...

The study will be carried out in partnership with The GOG Foundation and the European Network of Gynaecological Oncological ...

Positive new data suggests that more people facing advanced breast cancer may be able to put off treatment with harsh ...

The first patient has been dosed in the DESTINYEndometrial01 phase 3 trial evaluating Enhertu (trastuzumab deruxtecan) in combination with rilvegostomig or pembrolizumab versus platinum-based ...

Trastuzumab deruxtecan plus pertuzumab outperformed standard-of-care therapy as first-line treatment for HER2-positive ...

The DESTINY-Breast09 study, reported at ASCO, compared antibody-drug conjugate (ADC) Enhertu (trastuzumab deruxtecan) and ...

In the DESTINY-Breast09 study, Enhertu (fam-trastuzumab deruxtecan-nxki) plus pertuzumab reduced the risk of disease ...

In combination with rilvegostomig or Keytruda, Enhertu will be evaluated versus chemotherapy in the DESTINY-Endometrial01 ...

Adding Enhertu to Perjeta improved time without cancer growth versus standard care in advanced HER2-positive breast cancer, ...

"As early participants in these innovative drug reimbursement processes, AstraZeneca and Daiichi Sankyo are pleased to accelerate access to innovative treatments for Canadian patients ...

Confirmed objective response rate (ORR) with ENHERTU plus pertuzumab was 85.1% versus 78. ... the DESTINY-Breast09 results show trastuzumab deruxtecan combined with pertuzumab has the potential to ...